Spectral AI Reports Q3 2026 Financial Results Amid Transition to Commercial Operations
Spectral AI (MDAI) reported third-quarter 2026 results characterized by a strategic shift from research and development toward commercialization. The company experienced a decrease in R&D revenue to $2.9 million due to a narrower project scope under its BARDA contract, while gross margins compressed to 27.2% as the firm began funding shared development costs. The company reported a net loss of $3.7 million ($0.11 per share) and a cash balance of $11.2 million. While management is focusing on integrating its DeepView AI system into clinical workflows, they noted a delay in international regulatory clearance, now expected in early 2027. This delay pushes the commencement of initial sales in markets like the U.K., Australia, or the GCC further out.
Tickers: $MDAI
Topics: earnings report financial guidance net loss R&D spending revenue decrease
Read the full article at Motley Fool
Part of the story Stantec Scheduled to Report Q3 2026 Earnings on November 12 (5 articles)